{
    "clinical_study": {
        "@rank": "74021", 
        "arm_group": [
            {
                "arm_group_label": "Phase Ib. APR-246 + Carboplatin/PLD.", 
                "arm_group_type": "Experimental", 
                "description": "Dose escalation of APR-246."
            }, 
            {
                "arm_group_label": "Phase II: Arm A. APR-246 + Carboplatin/PLD.", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Phase II: Arm B. Carboplatin/PLD.", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to make a preliminary assessment of the efficacy of a combined\n      APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy\n      regimen alone, in patients with platinum sensitive recurrent high grade serous ovarian\n      cancer (HGSOC) with mutated p53. In addition, the study aims to assess the safety profile of\n      the combined APR-246 and carboplatin/PLD chemotherapy regimen compared with carboplatin/PLD\n      chemotherapy regimen alone, to evaluate potential biomarkers, and to assess the biological\n      activity in tumor and surrogate tissues."
        }, 
        "brief_title": "p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246", 
        "condition": "Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed High Grade Serous Ovarian Cancer, and positive nuclear immunohistochemical\n             (IHC) staining for p53\n\n          -  Disease Progression between 6-24 months after a first or second platinum based\n             regimen\n\n          -  At least a single measurable lesion. Phase II patients only\n\n          -  Adequate organ function prior to registration\n\n          -  Toxicities from previous cancer therapies must have recovered to grade 1 (defined by\n             Common Terminology Criteria for Adverse Events [CTCAE] 4.0) Chronic stable grade 2\n             peripheral neuropathy secondary to neurotoxicity from prior therapies may be\n             considered on a case by case basis\n\n          -  ECOG performance status of 0 to 1\n\n        Exclusion Criteria:\n\n          -  Prior exposure to cumulative doses of doxorubicin >400 mg/m2 or epirubicin >720 mg/m2\n\n          -  History of allergic reactions to carboplatin, platinum containing compounds or\n             mannitol and/or hypersensitivity to PLD or to any of the excipients\n\n          -  Unable to undergo imaging by either CT scan or MRI\n\n          -  Evidence of any other medical conditions (such as psychiatric illness, infectious\n             diseases, neurological conditions, physical examination or laboratory findings) that\n             may interfere with the planned treatment, affect patient compliance or place the\n             patient at high risk from treatment related complications\n\n          -  Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or\n             carcinoma in situ)\n\n          -  Is taking concurrent (or within 4 week prior to registration) chemotherapy,\n             immunotherapy, radiotherapy, or any ancillary therapy that is considered to be\n             investigational (i.e., used for non-approved indications(s) and in the context of a\n             research investigation). Supportive care measures are allowed"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02098343", 
            "org_study_id": "APR-407"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Phase Ib. APR-246 + Carboplatin/PLD.", 
                    "Phase II: Arm A. APR-246 + Carboplatin/PLD."
                ], 
                "description": "Intravenous infusion.", 
                "intervention_name": "APR-246", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Phase Ib. APR-246 + Carboplatin/PLD.", 
                    "Phase II: Arm A. APR-246 + Carboplatin/PLD.", 
                    "Phase II: Arm B. Carboplatin/PLD."
                ], 
                "description": "Intravenous infusion.", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Phase Ib. APR-246 + Carboplatin/PLD.", 
                    "Phase II: Arm A. APR-246 + Carboplatin/PLD.", 
                    "Phase II: Arm B. Carboplatin/PLD."
                ], 
                "description": "Intravenous infusion.", 
                "intervention_name": "Pegylated Liposomal Doxorubicin Hydrochloride (PLD)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ovarian cancer", 
            "Ovarian carcinoma", 
            "High Grade Serous Ovarian Cancer", 
            "Recurrent Cancer", 
            "Resistant Cancer"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "link": {
            "description": "Aprea AB's website (Sponsor)", 
            "url": "http://www.aprea.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "B-3000"
                    }, 
                    "name": "Leuven University Hospitals"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom", 
                        "zip": "CB2 0QQ"
                    }, 
                    "name": "Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom", 
                        "zip": "EH4 2XR"
                    }, 
                    "name": "Edinburgh Cancer Research Centre, The University of Edinburgh"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "W12 0NN"
                    }, 
                    "name": "Imperial College London, Hammersmith Hospital Campus"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "United Kingdom"
            ]
        }, 
        "official_title": "PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246", 
        "overall_contact": {
            "email": "Mikael.vonEuler@aprea.com", 
            "last_name": "Mikael von Euler, MD PhD FFPM"
        }, 
        "overall_official": {
            "affiliation": "Coordinating Investigator. Clatterbridge Centre for Oncology, UK", 
            "last_name": "John A Green, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "DLT: Hematological and non-hematological toxicities according to grade/days stated in the protocol.", 
                "measure": "Phase Ib: Dose-limiting toxicities (DLT) (see Description) of combined APR-246 and carboplatin/PLD regimen", 
                "time_frame": "Until the end of the first treatment cycle, i.e., Day 28"
            }, 
            {
                "description": "Safety Analysis: Adverse events (AEs) will be summarized by body system, preferred term, severity, and relationship to treatment. Serious adverse events, deaths, and AEs leading to early discontinuation of study drug will be summarized. Laboratory parameters will be summarized.", 
                "measure": "Phase Ib: Safety Profile (see Description) of combined APR-246 and carboplatin/PLD regimen", 
                "time_frame": "Until 30 days after the last administration of study treatment to the patient"
            }, 
            {
                "measure": "Phase Ib: Maximum observed plasma concentration (Cmax) of APR-246", 
                "time_frame": "Until Day 5 in cycle 1"
            }, 
            {
                "measure": "Phase Ib: Area under the plasma concentration-time curve (AUC) of APR-246", 
                "time_frame": "Until Day 5 in cycle 1"
            }, 
            {
                "measure": "Phase II: Progression Free Survival (PFS)", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "reference": {
            "PMID": "22965953", 
            "citation": "Lehmann S, Bykov VJ, Ali D, Andr\u00e9n O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson PO. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012 Oct 10;30(29):3633-9. doi: 10.1200/JCO.2011.40.7783. Epub 2012 Sep 10."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02098343"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time frame from registration to the date of death from any cause.", 
                "measure": "Phase II: Overall Survival (OS)", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "measure": "Phase II: Overall Response Rate (RR)", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "Safety Analysis: Adverse events will be summarized by body system, preferred term, severity, and relationship to treatment. Serious adverse events, deaths, and AEs leading to early discontinuation of study drug will be summarized. Laboratory parameters will be summarized.", 
                "measure": "Phase II: Safety Profile (see Description) of combined APR-246 and carboplatin/PLD regimen or the carboplatin/PLD regimen alone", 
                "time_frame": "Until 30 days after the last administration of study treatment to the patient."
            }
        ], 
        "source": "Aprea AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aprea AB", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}